Related Experiment Video
Updated: Dec 26, 2025

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments
Published on: October 25, 2016
Transient Receptor Potential Channels and Inflammatory Bowel Disease
Yiding Chen1,2, Jingxi Mu1,2, Min Zhu1,2
1Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Transient receptor potential (TRP) channels in the gut regulate inflammation and immunity. Targeting these channels shows promise for treating inflammatory bowel disease (IBD) and visceral hypersensitivity.
Area of Science:
- Gastroenterology
- Immunology
- Channelopathies
Background:
- Transient receptor potential (TRP) cation channels are crucial sensors in the gastrointestinal (GI) tract.
- They act as transducers for G-protein coupled receptors and regulate GI homeostasis.
- Dysfunctional TRP channels are implicated in inflammatory bowel disease (IBD) pathogenesis.
Purpose of the Study:
- To comprehensively review the functions of TRP channels, focusing on their roles in immunity and IBD.
- To discuss the involvement of TRP channels in visceral hypersensitivity (VHS) and immune responses within IBD.
- To explore TRP channels as potential therapeutic targets for IBD.
Main Methods:
- Literature review of human and animal studies.
- Analysis of TRP channel involvement in GI homeostasis and inflammation.
- Synthesis of current understanding of TRP channel function in IBD and VHS.
Main Results:
- TRP channels are implicated in neurogenic inflammation and immune cell regulation in the GI tract.
- Evidence links TRP channels to visceral hypersensitivity and immune pathogenesis in IBD.
- TRP channels can exacerbate or ameliorate IBD symptoms and inflammation.
Conclusions:
- TRP channels play a significant role in the immune aspects of IBD and associated visceral hypersensitivity.
- TRP channels represent a promising therapeutic target for novel IBD treatments.
- Further research is needed to clarify contradictory findings and optimize therapeutic strategies.
More Related Videos
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF